Compile Data Set for Download or QSAR
maximum 50k data
Found 440 with Last Name = 'knight' and Initial = 'jl'
LigandPNGBDBM602728(2-[1-(2-Isoindolin-2-yl-6-methyl-4-oxo-chromen-8-y...)
Affinity DataIC50:  110nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGag-Pol polyprotein [600-1028,C879S]/[600-1151,C879S](Human immunodeficiency virus type 1)
Rutgers University

LigandPNGBDBM33960(dihydroxy benzoyl naphthyl hydrazone (DHBNH) analo...)
Affinity DataIC50:  400nMpH: 7.8 T: 2°CAssay Description:HIV-1 RT RDDP activity was generally determined by a fixed time assay. Briefly, reaction mixtures contained p51/p66 RT, template-primer, and [3H]-TTP...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Homo sapiens (Human))
Petra Pharma

US Patent
LigandPNGBDBM602728(2-[1-(2-Isoindolin-2-yl-6-methyl-4-oxo-chromen-8-y...)
Affinity DataIC50:  450nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602702(US11649227, Example 310 | US20230286960, Example 3...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602702(US11649227, Example 310 | US20230286960, Example 3...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602703(US11649227, Example 319 | US20230286960, Example 3...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602704(2-[1-(6-Fluoro-2-isoindolin-2-yl-3-methyl-4-oxo-ch...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602704(2-[1-(6-Fluoro-2-isoindolin-2-yl-3-methyl-4-oxo-ch...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602705(2-[1-[2-(4,4-Difluoro-1-piperidyl)-6-fluoro-3-meth...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602705(2-[1-[2-(4,4-Difluoro-1-piperidyl)-6-fluoro-3-meth...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602706(2-[1-[2-(6-Azaspiro[2.5]octan-6-yl)-6-fluoro-3-met...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602706(2-[1-[2-(6-Azaspiro[2.5]octan-6-yl)-6-fluoro-3-met...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602707(US11649227, Example 335 | US20230286960, Example 3...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602708(2-[1-[2-(5-Cyanoisoindolin-2- yl)-4-oxo-6- (triflu...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602708(2-[1-[2-(5-Cyanoisoindolin-2- yl)-4-oxo-6- (triflu...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602709(2-[1-[2-Isoindolin-2-yl-4-oxo-6-(trifluoromethyl)c...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602709(2-[1-[2-Isoindolin-2-yl-4-oxo-6-(trifluoromethyl)c...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602710(US11649227, Example 343 | US20230286960, Example 3...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602711(2-[1-[2-Isoindolin-2-yl-3-methyl-4-oxo-6-(trifluor...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602712(US11649227, Example 349 | US20230286960, Example 3...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602712(US11649227, Example 349 | US20230286960, Example 3...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602714(US11649227, Example 362 | US20230286960, Example 3...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602715(US11649227, Example 370 | US20230286960, Example 3...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602718(US11649227, Example 376 | US20230286960, Example 3...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602723(US11649227, Example 396 | US20230286960, Example 3...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602724(US11649227, Example 398 | US20230286960, Example 3...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602725(US11649227, Example 399 | US20230286960, Example 3...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602726(US11649227, Example 400 | US20230286960, Example 4...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602726(US11649227, Example 400 | US20230286960, Example 4...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM618133(2-[1-[2-(6-Azabicyclo[3.1.1]heptan-6-yl)-6-methyl-...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602709(2-[1-[2-Isoindolin-2-yl-4-oxo-6-(trifluoromethyl)c...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602709(2-[1-[2-Isoindolin-2-yl-4-oxo-6-(trifluoromethyl)c...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602710(US11649227, Example 343 | US20230286960, Example 3...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602711(2-[1-[2-Isoindolin-2-yl-3-methyl-4-oxo-6-(trifluor...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602712(US11649227, Example 349 | US20230286960, Example 3...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602712(US11649227, Example 349 | US20230286960, Example 3...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602714(US11649227, Example 362 | US20230286960, Example 3...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602715(US11649227, Example 370 | US20230286960, Example 3...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602718(US11649227, Example 376 | US20230286960, Example 3...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602723(US11649227, Example 396 | US20230286960, Example 3...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602724(US11649227, Example 398 | US20230286960, Example 3...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602725(US11649227, Example 399 | US20230286960, Example 3...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602726(US11649227, Example 400 | US20230286960, Example 4...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602726(US11649227, Example 400 | US20230286960, Example 4...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602727(2-[1-[2-(6-Azabicyclo[3.1.1]heptan-6-yl)-6-methyl-...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6×his tagged p110<...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602616(5-Cyano-2-[1-[2-(4,4-dimethyl-1- piperidyl)-6-meth...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602619(2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602620(2-(4,4-Dimethyl-1-piperidyl)-6-methyl- 8-[1-[2-(1H...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602628(2-[1-[3-Cyclopropyl-2-(4,4-dimethyl-1- piperidyl)-...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM602629(2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- isoxazol-4-y...)
Affinity DataIC50: <500nMAssay Description:Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 440 total ) | Next | Last >>
Jump to: